Qiagen N.V. / QIAGEN Reports Strong Fourth Quarter and Fiscal 2009 Results processed and transmitted by Hugin AS. The issuer is solely responsible for the content of this announcement. 

Fiscal 2009 Net Sales Exceed $1 Billion


Venlo, The Netherlands, February 8, 2010 - QIAGEN N.V. (Nasdaq: QGEN; Frankfurt,
Prime  Standard: QIA) today  announced the results  of operations for the fourth
quarter and the fiscal year ended December 31, 2009.

The  reported net  sales for  the fourth  quarter 2009 exceeded the guidance and
reported  net sales and adjusted earnings per share for fiscal year 2009 were at
the  high  end  of  company's  expectations  provided by the Company on November
9, 2009. Reported  net sales for fiscal 2009 exceeded US$1 billion for the first
time in the Company's history.

Fourth Quarter 2009 Results

+----------------------------------------------------------------------------+
|QIAGEN's Fourth Quarter 2009                                                |
+----------------------------------------------------------------------------+
|in US$ millions, except per share information Q4 2009 Q4 2008         Growth|
+----------------------------------------------------------------------------+
|                                                                            |
|                                                                            |
|Net sales                                       289.1   237.2            22%|
|                                                                            |
|Net sales at constant exchange rates            272.1   237.2            15%|
|                                                                            |
|Operating income, adjusted                       83.4    66.6            25%|
|                                                                            |
|Net income, adjusted                             57.6    43.7            32%|
|                                                                            |
|EPS, adjusted( )(US$)                            0.24    0.22             9%|
|                                                                            |
|                                                                            |
+----------------------------------------------------------------------------+

 For information on the adjusted figures, please refer to the reconciliation
 table

 accompanying this release.



The  Company reported that  consolidated net sales  for its fourth quarter 2009
increased  22% to  $289.1  million  from  $237.2  million in the same quarter of
2008. Excluding  the favorable impact from  foreign currency exchange rates, net
sales  for  the  fourth  quarter  2009 would  have increased 15% from the fourth
quarter  2008. Reported operating income  for the quarter  increased 6% to $42.9
million  from $40.4 million in the same  quarter of 2008, and net income for the
quarter increased 80% to $44.5 million from $24.7 million in the same quarter of
2008. Diluted  earnings per share for the  fourth quarter increased 50% to $0.18
in  2009 (based on 241.0 million  weighted average shares  and share equivalents
outstanding)  from $0.12 in 2008 (based on 202.0 million weighted average shares
and share equivalents outstanding).

On  an adjusted  basis, fourth  quarter operating  income increased 25% to $83.4
million in 2009 from $66.6 million in 2008, and fourth quarter 2009 adjusted net
income  increased  32% to  $57.6  million  from  $43.7 million in 2008. Adjusted
diluted  earnings per share  increased to $0.24  in the fourth quarter 2009 from
$0.22 in 2008.

Fiscal Year 2009 Results

+----------------------------------------------------------------------------+
|QIAGEN's Fiscal Year 2009                                                   |
+----------------------------------------------------------------------------+
|in US$ millions, except per share information 12M 2009 12M 2008       Growth|
+----------------------------------------------------------------------------+
|                                                                            |
|                                                                            |
|Net sales                                      1,009.8    893.0          13%|
|                                                                            |
|Net sales at constant exchange rates           1,038.6    893.0          16%|
|                                                                            |
|Operating income, adj.                           296.1    252.7          17%|
|                                                                            |
|Net income, adj.                                 199.6    163.3          22%|
|                                                                            |
|EPS, adj.( )(US$)                                 0.93     0.80          16%|
|                                                                            |
|                                                                            |
+----------------------------------------------------------------------------+

 For information on the adjusted figures, please refer to the reconciliation
 table

 accompanying this release.



For  the  year  ended  December  31, 2009, net  sales  increased 13% to $1,009.8
million  compared to  $893.0 million  in 2008. Excluding  the unfavorable impact
from  foreign currency exchange rates, net  sales for the fiscal year 2009 would
have  increased 16%. Operating income as reported for fiscal 2009 increased 24%
to  $180.2  million  from  $145.7  million  in 2008. Net income increased 55% to
$137.8  million  from  $89.0  million  in  2008, and  diluted earnings per share
increased  45% to $0.64 in 2009 (based  on 213.6 million weighted average shares
and  share equivalents outstanding)  from $0.44 in  2008 (based on 204.3 million
weighted average shares and share equivalents outstanding).

On  an adjusted  basis, operating  income for  the year ended December 31, 2009
increased  17% to  $296.1  million  in  2009 from  $252.7  million  in 2008, and
adjusted  net  income  increased  22% to  $199.6  million  from  $163.3 million.
Adjusted  diluted earnings per  share in fiscal  2009 increased 16% to $0.93 per
share from $0.80 per share in 2008.

QIAGEN's  fourth quarter  and fiscal  year 2009 results  include the  results of
operations from the Company's recent acquisitions, the most significant of which
were SABiosciences Corporation, acquired in December 2009, DxS Ltd., acquired in
September   2009, and   Corbett   Life   Sciences,   acquired   in  July  2008.
Reconciliations  of  reported  results  determined  in accordance with generally
accepted  accounting principles (GAAP)  to adjusted results  are included in the
tables accompanying this release.

 "2009  was a very successful year for QIAGEN," said Peer Schatz, QIAGEN's Chief
Executive  Officer. "Net sales and  adjusted net income demonstrated significant
growth.  Net  sales  grew  22% -  significantly  faster  than the overall market
growth. Strong growth in net sales and adjusted net income as well as an organic
growth  rate of 13% define the most successful year in the company's history and
drove  revenues  to  surpass  the  $1  billion  mark.  The  solid  foundation of
innovation-driven,  organic growth also  allows us to  plan for strong growth in
2010 and beyond.

The  largest revenue share we recorded for fiscal 2009 was in sales to customers
in molecular diagnostics (approximately 47% of total revenues) followed by sales
to  customers  in  academia  (approximately  26% of  total  revenues), in pharma
(approximately  21% of total revenues) and in applied testing (approximately 6%
of  total revenues). Growth  of our sales  to customers in molecular diagnostics
was  fueled by strong sales of  our profiling solutions (including our influenza
and  other infectious disease assays) as  well as products addressing prevention
(such  as  HPV  screening  and  genotyping) and personalized healthcare testing.
Sales  to  customers  in  the  pharmaceutical  and  biotech  industry conducting
clinical  development  continued  to  experience  solid growth during the fourth
quarter,  academic  research  markets  continued  to  perform solidly and we are
looking  forward to the effect  of the stimulus programs  which are expected for
2010 and into 2011.

Our   acquisition  strategy  remains  focused,  consistent  and  value-creating,
providing complementary technologies, new commercial capabilities and geographic
reach.  For  example,  during  2009 we  further  strengthened our strong content
engine  for  research  and  molecular  diagnostics  assays.  In December 2009 we
acquired  SABiosciences  and  added  a  portfolio  of PCR-based, pathway-focused
panels   that   represent   highly   efficient   solutions   for   pathway-  and
disease-biomarker  discovery  and  development  and diagnostics development. The
acquisition  of DxS Ltd. in September  2009 combined two leadership positions in
companion  diagnostics to  create a  very powerful  leader in a transformational
area of healthcare: personalized healthcare.

In  addition we formed a  very promising position in  point of need testing. The
acquisition  of  ESE  GmbH  in  January  2010 added  to QIAGEN's instrumentation
platform  a portable,  battery operated,  "ultra-fast time  to result", analysis
system.  This platform can run QIAGEN assay technologies in formats suitable for
point  of need testing in healthcare and applied testing (e.g. veterinary, food,
environmental,   biodefense  testing),  and  in  all  other  settings,  where  a
laboratory infrastructure is not accessible and low-throughput molecular testing
and fast turnaround is required.

All  three transactions contribute  to key elements  of our strategy  to lead in
molecular  diagnostics-based prevention, profiling,  personalized healthcare and
point  of need  testing. With  different platform  technologies that address all
needs  in terms of throughput, flexibility in assay technologies, convenience in
handling and efficiency in performance, an industry leading assays portfolio and
a  pipeline that provides us with an ongoing  stream of new assays to launch, we
are  excellently  positioned  not  only  to  participate  from but also to shape
current and future trends in molecular based testing and life science research."

"QIAGEN  experienced a  successful fiscal  year 2009 with  reported revenues and
adjusted  earnings per share at  the high end of  our expectations," said Roland
Sackers, QIAGEN's Chief Financial Officer. "Assuming constant exchange rates for
both  fiscal years  revenue growth  was 16% and  was fueled  by a strong organic
growth  of  13%, adjusted  for  the  divesture  of certain assets related to our
activities in HLA diagnostics (transplantation diagnostics) in July 2009.

Our  consumable  products  portfolio  contributed  10% growth  (13%  at constant
exchange  rates) in fiscal  year 2009 and our  sales of instrumentation products
recorded a growth rate of 37% (42% at constant exchange rates). Net sales in the
Americas  for  fiscal  year  2009 represented  approximately  49% of our overall
business  and recorded a growth rate of 10% (12% at constant exchange rates) and
European  sales,  which  represent  approximately  36% of our revenues, showed a
growth  rate of 11% (19% at constant exchange rates). Net sales in Asia remained
strong, showing a growth rate of 39% (36% at constant exchange rates)."

Fiscal Year 2010 Guidance
Based  on foreign currency exchange rates as of January 31, 2010, QIAGEN expects
revenues  between $1,120 and $1,170 million in 2010 with a growth rate of 11% to
16% when  compared to 2009 and adjusted diluted earnings per share between $0.90
and  $0.96 including a diluting effect of $0.02 following the DxS acquisition in
September 2009. Based on foreign currency exchange rates as of November 9, 2009
(the date of the Company's third quarter 2009 earnings conference call), revenue
guidance for 2010 would have been approximately $35 million higher.

QIAGEN - Sample and Assay Technologies Highlights
·          QIAGEN established the QIAGENcares program to support regions in need
for  effective diagnostic testing solutions and announced the first two programs
under this Corporate Social Responsibility program:
o     QIAGEN  and  the  Chittaranjan  National  Cancer Institute (CNCI) formed a
collaboration  to  establish  the  first  large-scale  cervical cancer screening
program  for women in Kolkata,  India. The initiative will  be conducted over 5
years and is expected to reach 50,000 women.
o     QIAGEN agreed to donate one million HPV  tests over the run of this cancer
screening program.
·          QIAGEN entered into an agreement to supply molecular sample and assay
technologies  for a new national, PCR-based  blood screening program for HIV and
Hepatitis  C  (HCV)  in  Brazil.  QIAGEN  will  provide Bio-Manguinhos, the main
provider of vaccines and diagnostics to the Brazilian Ministry of Health, with a
significant   volume   of   molecular  testing  solutions  -  sample  and  assay
technologies,  related instrumentation,  operational know-how  and training. The
agreement  is expected to run for five years and contains options for subsequent
extensions.
·          QIAGEN  significantly  expanded  its  strategic position in molecular
diagnostics:
o    QIAGEN acquired Explera s.r.l., a leading supplier in molecular diagnostics
and personalized medicine in Italy. With this acquisition QIAGEN is doubling the
size  of its molecular diagnostics sales channel  in Italy and is adding several
activities  in the area of personalized medicine and access to a suite of CE-IVD
pyrosequencing assays.
o     QIAGEN  acquired  DxS  Ltd.,  a  developer  and  manufacturer of companion
diagnostic   products   (CDx)  for  Personalized  Healthcare  (PHC).  With  this
acquisition,  QIAGEN has added to  its own activities in  CDx and taken a strong
leadership position in the new era of PHC.
o     QIAGEN acquired SABiosciences. This  transaction added to QIAGEN's product
offering a leading portfolio of PCR-based, disease and pathway-based panels that
play  key roles in biomedical  research and the development  of future drugs and
diagnostics.
o    QIAGEN acquired ESE GmbH, a developer and manufacturer of portable, battery
operated,  "ultra-fast time  to result",  multiplex UV  and fluorescence optical
measurement  devices which enable low-throughput molecular testing in practices,
emergency  rooms,  remote  field  areas,  and  other settings where a laboratory
infrastructure is not accessible and fast turnaround is required.
·          QIAGEN  launched  79 new  products  in  the  area  of  Sample & Assay
Technologies  including the PAXgene Blood miRNA kit for use in cancer, biomarker
and  miRNA  research  and  the  QIAamp  Circulating  Nucleic Acid kit for sample
preparation  in prenatal or other circulating nucleic acid research. In addition
QIAGEN  launched  a  number  of  assay  technologies  including two multiplexed,
PCR-based  CE-marked digene  HPV Genotyping  Tests, a  next generation CE marked
mutation profiling KRAS test as well as a BRAF test for use in cancer treatments
and   assay   technologies   for   epigenetic   methylation  analysis  based  on
pyrosequencing technology.
·          QIAGEN and  Pfizer entered  into an  agreement to develop a companion
diagnostic   assay  for  PF-04948568  (CDX-110),  an  immunotherapy  vaccine  in
development  for the  treatment of  glioblastoma multiforme  (GBM). Glioblastoma
multiforme is the most common malignant primary brain tumor in adults and occurs
in  around 25,000 patients  worldwide each  year. Pfizer's  investigational drug
PF-04948568  (CDX-110)  is  a  peptide  vaccine which targets the tumor-specific
Epidermal  Growth Factor Receptor variant III  (EGFRvIII), a mutated form of the
epidermal growth factor receptor that is only present in cancer cells and occurs
in  25-40 percent of GBM tumors. The QIAGEN  assay is designed to identify those
patients   whose   tumors  express  the  EGFRvIII  mutation,  allowing  for  the
possibility of more targeted and personalized treatment.
·         QIAGEN acquired a global and exclusive license for biomarker PI3K from
John  Hopkins University and intends to develop PCR and real time-PCR assays for
companion  diagnostic use  with certain  cancer treatments.  A number of studies
suggest  that  mutations  in  the  PI3K  oncogene  are indicative for successful
antibody  treatment of patients  suffering from lung,  breast and other cancers.
The  license includes all countries and allows QIAGEN to enter partnerships with
pharmaceutical  companies  to  develop  and  market  tests  for  new cancer drug
candidates.

Conference Call and Webcast Details
Detailed  information  on  QIAGEN's  business  and financial performance will be
presented  during  its  conference  call  on  February 9, 2010 at 9:30am ET. The
corresponding  presentation  slides  will  be  available  for  download  on  the
Company's          website         at         www.qiagen.com/goto/ConferenceCall
< http://www.qiagen.com/goto/ConferenceCall>.  A webcast  of the  conference call
will     also     be     available     at     www.qiagen.com/goto/ConferenceCall
< http://www.qiagen.com/goto/ConferenceCall>.

Use of Adjusted Results
QIAGEN  has regularly reported adjusted results  to give additional insight into
its financial performance as well as considered results on a constant currencies
basis. Adjusted results should be considered in addition to the reported results
prepared in accordance with generally accepted accounting principles, but should
not  be considered as a substitute. The Company believes certain items should be
excluded  from  adjusted  results  when  they  are  outside  of its ongoing core
operations,   vary   significantly   from   period  to  period,  or  affect  the
comparability  of  results  with  the  Company's  competitors  and its own prior
periods. Reconciliations of reported results to adjusted results are included in
the tables accompanying this release.

About QIAGEN
QIAGEN  N.V., a Netherlands  holding company, is  the leading global provider of
sample  and  assay  technologies.  Sample  technologies  are used to isolate and
process  DNA, RNA and proteins from biological  samples such as blood or tissue.
Assay  technologies are used to make these isolated biomolecules visible. QIAGEN
has  developed and markets  more than 500 sample  and assay products  as well as
automated  solutions for such consumables. The  Company provides its products to
molecular  diagnostics  laboratories,  academic  researchers, pharmaceutical and
biotechnology  companies,  and  applied  testing  customers for purposes such as
forensics,  animal or food testing  and pharmaceutical process control. QIAGEN's
assay  technologies include one  of the broadest  panels of molecular diagnostic
tests  available worldwide. This panel includes  the first FDA-approved test for
human papillomavirus (HPV), the primary cause of cervical cancer. QIAGEN employs
nearly  3,500 people in  over 30 locations  worldwide. Further information about
QIAGEN can be found at  http://www.qiagen.com/.

Certain  of  the  statements  contained  in  this news release may be considered
forward-looking  statements  within  the  meaning  of  Section  27A of  the U.S.
Securities  Act  of  1933, as  amended,  and  Section 21E of the U.S. Securities
Exchange  Act of  1934, as amended.  To the  extent that  any of  the statements
contained  herein relating to QIAGEN's  products, markets, strategy or operating
results,   including   without   limitation   expected  operating  results,  are
forward-looking,   such   statements  are  based  on  current  expectations  and
assumptions that involve a number of uncertainties and risks. Such uncertainties
and  risks include, but are not limited  to, risks associated with management of
growth   and   international  operations  (including  the  effects  of  currency
fluctuations,  regulatory processes and dependence on logistics), variability of
operating  results  and  allocations  between  business segments, the commercial
development  of  the  applied  testing  markets,  personal  healthcare  markets,
clinical  research markets  and proteomics  markets, women's  health/HPV testing
markets,   nucleic   acid-based   molecular   diagnostics  market,  and  genetic
vaccination  and gene  therapy markets,  changing relationships  with customers,
suppliers  and strategic partners,  competition, rapid or  unexpected changes in
technologies,   fluctuations   in   demand   for  QIAGEN's  products  (including
fluctuations  due  to  general  economic  conditions,  the  level  and timing of
customers'   funding,  budgets,  and  other  factors),  our  ability  to  obtain
regulatory   approval   of   our  infectious  disease  panels,  difficulties  in
successfully  adapting QIAGEN's  products to  integrated solutions and producing
such products, the ability of QIAGEN to identify and develop new products and to
differentiate  and  protect  its  products  from  competitors'  products, market
acceptance of QIAGEN's new products and the integration of acquired technologies
and  businesses. For  further information,  refer to  the discussions in reports
that  QIAGEN has filed with,  or furnished to, the  U.S. Securities and Exchange
Commission (SEC).

                                      ###





                                  QIAGEN N.V.

                  CONDENSED CONSOLIDATED STATEMENTS OF INCOME

                                  (unaudited)



                                                         Three months

 (in thousands,
 except per share
 data)                                                ended December 31,
                                              ----------------------------------


                                                    2009             2008
                                              ----------------------------------
 Net sales                                         $  289,077        $ 237,182

 Cost of sales                                        100,965           79,731
                                              ----------------------------------
 Gross profit                                         188,112          157,451
                                              ----------------------------------

 Operating expenses:

                   Research and development            30,560           28,049

                   Sales and marketing                 68,957           59,662

                   General and
                   administrative,
                   integration and other               39,723           25,265

                   Acquisition-related
                   intangible amortization              5,933            3,884

                   Purchased in-process
                   research and development               -                155
                                              ----------------------------------
 Total operating expenses                             145,173          117,015
                                              ----------------------------------

 Income from operations                                42,939           40,436
                                              ----------------------------------

 Other income (expense):

                   Interest income                        980            2,121

                   Interest expense                    (7,504)          (8,695)

                   Other income, net                   12,996            2,311
                                              ----------------------------------
 Total other income (expense)                           6,472           (4,263)
                                              ----------------------------------

 Income before provision for income taxes              49,411           36,173

 Provision for income taxes                             4,947           11,490
                                              ----------------------------------
                                                      $                $
 Net income attributable to QIAGEN N.V.                44,464           24,683



                   Weighted average number of
                   diluted common shares              241,018          202,039


                   Diluted net income
                   attributable to QIAGEN N.V.
                   per common share                   $  0.18           $ 0.12


                   Diluted net income
                   attributable to QIAGEN
                   N.V. per common share,
                   adjusted                            $ 0.24           $ 0.22





                                  QIAGEN N.V.

                  CONDENSED CONSOLIDATED STATEMENTS OF INCOME

                                  (unaudited)



                                                           Twelve months

 (in thousands,
 except per share
 data)                                                  ended December 31,
                                                   -----------------------------


                                                        2009           2008
                                                   -----------------------------
 Net sales                                           $ 1,009,825     $ 892,975

 Cost of sales                                           342,752       293,285
                                                   -----------------------------
 Gross profit                                            667,073       599,690
                                                   -----------------------------

 Operating expenses:

                      Research and development           107,900        97,331

                      Sales and marketing                244,814       227,408

                      General and administrative,
                      integration and other              115,933       113,936

                      Acquisition-related
                      intangible amortization             18,221        14,368

                      Purchased in-process
                      research and development               -             985
                                                   -----------------------------
 Total operating expenses                                486,868       454,028
                                                   -----------------------------

 Income from operations                                  180,205       145,662
                                                   -----------------------------

 Other income (expense):

                      Interest income                      3,522         9,511

                      Interest expense                   (29,641)      (37,527)

                      Other income, net                   18,244         1,640
                                                   -----------------------------
 Total other expense                                      (7,875)      (26,376)
                                                   -----------------------------

 Income before provision for income taxes and
 noncontrolling interest                                 172,330       119,286

 Provision for income taxes                               34,563        29,762
                                                   -----------------------------
 Net income                                              137,767        89,524
                                                   -----------------------------
 Less: Noncontrolling interest                                             491
                                                   -----------------------------
 Net income attributable to QIAGEN N.V.               $  137,767    $   89,033


                      Weighted average number of
                      diluted common shares              213,612       204,259


                      Diluted net income
                      attributable to QIAGEN N.V.
                      per common share                   $  0.64       $  0.44


                      Diluted net income
                      attributable to QIAGEN N.V.
                      per common share, adjusted         $  0.93       $  0.80








                                  QIAGEN N.V.

                     CONDENSED CONSOLIDATED BALANCE SHEETS




  (in thousands,
  except par
  value)                                   December 31,       December 31,

                                               2009               2008
                                         ---------------------------------------
 Assets                                    (unaudited)


 Current Assets:

                                                  $
  Cash and cash equivalents                     825,557         $      333,313


  Short-term investments                         40,000                      -


  Accounts receivable, net                      193,737                158,440


  Income taxes receivable                        12,907                 14,441


  Inventories, net                              130,851                108,563


  Prepaid expenses and other                     96,893                 61,424


  Deferred income taxes                          33,525                 27,374
                                         ---------------------------------------

                  Total current assets        1,333,470                703,555
                                         ---------------------------------------

 Long-Term Assets:


  Property, plant and equipment, net            317,467                289,672


  Goodwill                                    1,337,064              1,152,105


  Intangible assets, net                        752,296                640,309


  Deferred income taxes                          26,387                 73,766


  Other assets                                   29,780                 25,916
                                         ---------------------------------------

                  Total long-term assets      2,462,994              2,181,768
                                         ---------------------------------------
                                         ---------------------------------------
                                                     $
                 Total assets                 3,796,464          $   2,885,323


 Liabilities and Shareholders' Equity


 Current Liabilities:

                                                $
  Accounts payable                               43,775        $        48,836


  Accrued and other liabilities                 248,699                163,513


  Income taxes payable                           10,727                 14,288


  Current portion of long-term debt              50,000                 25,000

  Current portion of capital lease
  obligations                                     3,417                  2,984


  Deferred income taxes                          18,912                  7,754
                                         ---------------------------------------
                  Total current
                  liabilities                   375,530                262,375
                                         ---------------------------------------

 Long-Term Liabilities:


  Long-term debt, net of current portion        870,000                920,000

  Capital lease obligations, net of
  current portion                                27,554                 29,718


  Deferred income taxes                         212,690                212,589


  Other                                          19,521                  6,797
                                         ---------------------------------------
                  Total long-term
                  liabilities                 1,129,765              1,169,104
                                         ---------------------------------------

 Shareholders' Equity:

  Common shares, EUR .01 par value:

                 Authorized--410,000
                 shares

                 Issued and
                 outstanding--232,074
                 shares

                    in 2009 and 197,839
                 shares in 2008                   2,711                  2,212

                 Additional
                 paid-in-capital              1,622,733                958,665


                 Retained earnings              615,579                477,812

                 Accumulated other
                 comprehensive income            50,146                 15,155
                                         ---------------------------------------
                  Total QIAGEN N.V.
                  shareholders' equity        2,291,169              1,453,844
                                         ---------------------------------------
                                         ---------------------------------------
                 Total liabilities and               $
                 shareholders' equity         3,796,464          $   2,885,323




                                  QIAGEN N.V.

                 RECONCILIATION OF REPORTED TO ADJUSTED FIGURES

                                  (unaudited)



                      Three months ended December 31, 2009

                         (in millions, except EPS data)


                   Net    Gross  Operating  Pre-tax   Income    Net    Diluted
                  Sales  Profit    Income    Income    Tax     Income    EPS*
                ----------------------------------------------------------------
 Reported             $       $                   $        $        $       $
 results          289.1   188.1    $  42.9     49.4     (4.9)    44.5     0.18

 Adjustments:

  Business
  integration,
  acquisition
  related and
  restructuring
  costs             -       4.2       17.9     17.9     (6.3)    11.6     0.05

  Purchased
  intangibles
  amortization      -      14.3       20.2     20.2     (7.5)    12.7     0.05

  Share-based
  compensation      -       0.1        2.4      2.4     (0.7)     1.7     0.01

  Income from
  Divestitures
  and other
  acquisition
  related income    -       -          -      (10.5)    (2.4)   (12.9)   (0.05)
                ----------------------------------------------------------------
  Total
  adjustments       -       18.6       40.5     30.0   (16.9)     13.1    0.06
                ----------------------------------------------------------------
 Adjusted             $       $                   $        $        $        $
 results          289.1   206.7   $   83.4     79.4    (21.8)    57.6     0.24


 *  Using 241 Mio. diluted
 shares



                      Three months ended December 31, 2008

                         (in millions, except EPS data)


                   Net    Gross  Operating  Pre-tax   Income    Net    Diluted
                  Sales  Profit    Income    Income    Tax     Income    EPS*
                ----------------------------------------------------------------
 Reported             $       $                   $        $        $        $
 results          237.2   157.5    $  40.4     36.2    (11.5)    24.7     0.12

 Adjustments:

  Business
  integration,
  acquisition
  related and
  restructuring
  costs             -       1.0        5.8      5.8     (1.4)     4.4     0.03

  Purchased
  in-process R&D    -       -          0.2      0.2      -        0.2      -

  Purchased
  intangibles
  amortization      -      13.2       17.1     17.1     (4.9)    12.2     0.06

  Share-based
  compensation      -       0.2        3.1      3.1     (0.9)     2.2     0.01
                ----------------------------------------------------------------
  Total
  adjustments       -      14.4       26.2     26.2     (7.2)    19.0     0.10
                ----------------------------------------------------------------
 Adjusted             $       $                   $        $        $       $
 results          237.2   171.9    $  66.6     62.4    (18.7)    43.7     0.22


 *  Using 202 Mio. diluted
 shares





                                  QIAGEN N.V.

                 RECONCILIATION OF REPORTED TO ADJUSTED FIGURES

                                  (unaudited)



                     Twelve months ended December 31, 2009

                         (in millions, except EPS data)


                            Gross  Operating  Pre-tax   Income    Net   Diluted
                 Net Sales Profit    Income    Income    Tax    Income   EPS*
                ----------------------------------------------------------------
 Reported               $       $                   $        $       $       $
 results          1,009.8   667.1   $  180.2    172.3    (34.5)  137.8    0.64

 Adjustments:

  Business
  integration,
  acquisition
  related and
  restructuring
  costs               -       7.4       34.4     34.4    (11.3)   23.1    0.11

  Purchased
  intangibles
  amortization        -      53.6       71.8     71.8    (25.6)   46.2    0.22

  Share-based
  compensation        -       0.8        9.7      9.7     (2.9)    6.8    0.03

  Income from
  Divestitures
  and other
  acquisition
  related income      -       -          -      (12.9)    (3.2)  (16.1)  (0.08)

  Acquisition
  related
  write-off of
  prepaid
  expenses and
  other asset
  impairment          -       -          -        2.7     (0.9)    1.8    0.01
                ----------------------------------------------------------------
  Total
  adjustments         -       61.8      115.9    105.7   (43.9)    61.8   0.29
                ----------------------------------------------------------------
 Adjusted               $       $                   $        $       $       $
 results          1,009.8   728.9   $  296.1    278.0    (78.4)  199.6    0.93


 *  Using 214 Mio. diluted shares



                      Twelve months ended December 31, 2008

                         (in millions, except EPS data)


                            Gross  Operating  Pre-tax   Income    Net   Diluted
                 Net Sales Profit    Income    Income    Tax    Income   EPS*
                ----------------------------------------------------------------
  Reported              $       $                   $        $       $       $
  results           893.0   599.7   $  145.7    119.3    (29.8)   89.0    0.44

  Adjustments:

  Business
  integration,
  acquisition
  related and
  restructuring
  costs               -       1.4       33.5     33.5    (11.2)   22.3    0.11

  Purchased
  in-process R&D      -       -          1.0      1.0      -       1.0    0.01

  Purchased
  intangibles
  amortization        -      48.7       63.1     63.1    (21.1)   42.0    0.20

  Share-based
  compensation        -       1.0        9.4      9.4     (2.9)    6.5    0.03

  Acquisition
  related
  impairment          -       -          -        4.0     (1.5)    2.5    0.01
                ----------------------------------------------------------------
  Total
  adjustments         -      51.1      107.0    111.0    (36.7)   74.3    0.36
                ----------------------------------------------------------------
  Adjusted              $       $                   $        $       $       $
  results           893.0   650.8   $  252.7    230.3    (66.5)  163.3    0.80


  *  Using 205 Mio. diluted shares





Contacts:


 Roland Sackers                        Dr. Solveigh Mähler
 Chief Financial Officer               Director Investor Relations
 QIAGEN N.V.                           QIAGEN N.V.
 e-mail: roland.sackers@qiagen.com     +49 2103 29 11710
     e-mail: solveigh.maehler@qiagen.com
                                       

                                       Albert F. Fleury
                                       Associate Director Investor Relations
                                       North America
                                       QIAGEN N.V.
                                       +1 301 944 7028
                                       e-mail: albert.fleury@qiagen.com
                                       




[HUG#1381805]



 --- End of Message --- 

Qiagen N.V.
Spoorstraat 50 KJ Venlo Netherlands

WKN: 901626;ISIN: NL0000240000;Index:TecDAX,HDAX,TECH All Share,MIDCAP;Prime All Share;